Aminoglutethimide: a "side-effect" turned to therapeutic advantage.
D000305:Adrenal Cortex Hormones / Q000096:biosynthesis; D000310:Adrenal Gland Neoplasms / Q000188:drug therapy; D000309:Adrenal Insufficiency / Q000139:chemically induced; D000308:Adrenocortical Hyperfunction / Q000188:drug therapy*; D000328:Adult; D000616:Aminoglutethimide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000728:Androgens / Q000096:biosynthesis; D000814:Aniline Compounds / Q000627:therapeutic use*; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D002648:Child; D002784:Cholesterol / Q000378:metabolism; D003480:Cushing Syndrome / Q000188:drug therapy; D004967:Estrogens / Q000096:biosynthesis; D005260:Female; D006066:Gonads / Q000187:drug effects; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced; D008297:Male; D011728:Pyridones / Q000627:therapeutic use*; D051381:Rats
D000305:Adrenal Cortex Hormones; D000728:Androgens; D000814:Aniline Compounds; D000927:Anticonvulsants; D004967:Estrogens; D011728:Pyridones; D000616:Aminoglutethimide; D002784:Cholesterol